| Dr Robert Ardel Sammons Jr, MD PHD | |
|
1400 N 7th St, Mesa Behavioral Medicine Clinic Pc, Grand Junction, CO 81501-3004 | |
| (970) 241-1983 | |
| (970) 242-6135 |
| Full Name | Dr Robert Ardel Sammons Jr |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 50 Years |
| Location | 1400 N 7th St, Grand Junction, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073508495 | NPI | - | NPPES |
| 28579 | Other | CO | STATE OF CO REGISTRATIONS |
| 016862 | Medicaid | CO | |
| BS0652568 | Other | US DEPT OF JUSTICE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 28579 (Colorado) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tms Solutions Inc | 6002113057 | 4 |
| Tms Solutions Inc | 6002113057 | 4 |
| Tms Solutions Inc | 6002113057 | 4 |
| Tms Solutions Inc | 6002113057 | 4 |
News Archive
Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.
The U.S. Food and Drug Administration announced today that it has awarded five grants totaling up to $6 million per year over the next five years to Pediatric Device Consortia across the country that will provide advice and support services to innovators of children's medical devices.
The American Medical Association's House of Delegates — after a lengthy debate — voted to maintain its support for the health law's individual mandate.
PENTAX Medical, a healthcare industry leader in endoscopic imaging, and Hitachi-Aloka Medical, a global leader in ultrasound imaging, recently announced renewed collaborative efforts between the two global companies to enable further innovation in the development of Endoscopic Ultrasound Systems.
Bayer HealthCare announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the oral multi-kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer.
› Verified 1 days ago
| Entity Name | Tms Solutions Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255732632 PECOS PAC ID: 6002113057 Enrollment ID: O20160318001183 |
News Archive
Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.
The U.S. Food and Drug Administration announced today that it has awarded five grants totaling up to $6 million per year over the next five years to Pediatric Device Consortia across the country that will provide advice and support services to innovators of children's medical devices.
The American Medical Association's House of Delegates — after a lengthy debate — voted to maintain its support for the health law's individual mandate.
PENTAX Medical, a healthcare industry leader in endoscopic imaging, and Hitachi-Aloka Medical, a global leader in ultrasound imaging, recently announced renewed collaborative efforts between the two global companies to enable further innovation in the development of Endoscopic Ultrasound Systems.
Bayer HealthCare announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the oral multi-kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Ardel Sammons Jr, MD PHD 1400 N 7th St, Mesa Behavioral Medicine Clinic Pc, Grand Junction, CO 81501-3004 Ph: (970) 241-1983 | Dr Robert Ardel Sammons Jr, MD PHD 1400 N 7th St, Mesa Behavioral Medicine Clinic Pc, Grand Junction, CO 81501-3004 Ph: (970) 241-1983 |
News Archive
Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.
The U.S. Food and Drug Administration announced today that it has awarded five grants totaling up to $6 million per year over the next five years to Pediatric Device Consortia across the country that will provide advice and support services to innovators of children's medical devices.
The American Medical Association's House of Delegates — after a lengthy debate — voted to maintain its support for the health law's individual mandate.
PENTAX Medical, a healthcare industry leader in endoscopic imaging, and Hitachi-Aloka Medical, a global leader in ultrasound imaging, recently announced renewed collaborative efforts between the two global companies to enable further innovation in the development of Endoscopic Ultrasound Systems.
Bayer HealthCare announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the oral multi-kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer.
› Verified 1 days ago
Dr. Deborah Jo Stetler, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 515 28 3/4 Rd, Grand Junction, CO 81501 Phone: 970-241-6023 Fax: 970-242-8330 | |
Dr. Frank C Szvetecz, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 515 28 3/4 Rd, Grand Junction, CO 81501 Phone: 970-241-6023 | |
Dr. Jerry Keith Kubena Jr., MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 515 28 3/4 Rd, Grand Junction, CO 81501 Phone: 970-263-4918 | |
Dr. Francis E Lotrich, MD,PHD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 515 28 3/4 Rd, Grand Junction, CO 81501 Phone: 970-263-4918 | |
Jennifer Elizabeth Kennedy, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2501 Blichmann Avenue, Suite 115, Grand Junction, CO 81505 Phone: 970-255-7672 | |
Dr. William Paul Elsass, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 515 28 3/4 Rd, Grand Junction, CO 81501 Phone: 970-241-6023 |